Significant Experimental Decrease of the Hepatocellular Carcinoma Incidence in C3H/Sy Mice after Long-Term Administration of EB1089, a Vitamin D Analogue

Oncology Research

Volumn 13, Issue 5, 2002, Pages 261-268

  Sahpazidou, Despina ^a   Stravoravdi, Pelagia ^a   Toliou, Theano ^a   Geromichalos, George ^a   Zafiriou, George ^a   Natsis, Konstantinos ^b   Gigis, Panagiotis ^b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Chemoprevention; Preclinical study; Spontaneous tumors

Indexed keywords

CALCITRIOL; SEOCALCITOL; VITAMIN D DERIVATIVE; CALCIUM; DRUG DERIVATIVE; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPSY; BODY WEIGHT; CANCER CELL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; HEPATOMA CELL; HISTOPATHOLOGY; IN VITRO STUDY; LIVER; LIVER CELL CARCINOMA; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; BLOOD; C3H MOUSE; COMPARATIVE STUDY; INCIDENCE; LIVER TUMOR; METABOLISM; URINE;

ANIMALS; CALCITRIOL; CALCIUM; CARCINOMA, HEPATOCELLULAR; FEMALE; INCIDENCE; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; VITAMIN D;

EID: 0141958580     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504003108748311     Document Type: Article

References (28)

1. 3 for hepatocellular carcinoma in rats. Anticancer Res. 20: 2739-2744; 2000.
2. 3. A potential new treatment for hepatocellular carcinoma. Anticancer Res. 20: 2705-2710; 2000.
3. Akhter, J.; Hassiotis, V.; Bolton, E.; Morris, D. L. Profound inhibition of human hepatoma cell line by vitamin D3 and analogues. Aust. NZ J. Surg. 68:520; 1988.
4. 3. Cancer Lett. 151:27-102; 2000.
5. Hansen, C. M.; Hamberg, K. J.; Binderup, E.; Binderup, L. Seocalcitol (EB1089): A vitamin D analogue of anticancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr. Pharm. Des. 6(7): 803-827; 2000.
6. 3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Mol. Biol. 58(4):395-401; 1996.
7. Hansen, C. M.; Maenpaa, P. H. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem. Pharmacol. 1(54):1173-1179; 1997.
8. Kissmeyer, A. M.; Binderup, E.; Binderup, L.; Mork Hansen, C.; Andersen, N. R.; Makin, H. L.; Schroeder, N. J.; et al. Metabolism of the vitamin D analog EB1089: Identification of in vivo and in vitro liver metabolites and their biological activities. Biochem. Pharmacol. 53(8):1087-1097; 1997.
9. 3 analogue EB1089. Eur. J. Cancer 32A(5):842-848; 1996.
10. Thomas, M. G.; Tebbutt, S.; Williamson, R. C. N. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 33: 1660-1663; 1992.
11. 3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res. 60(8):2304-2312; 2000.
12. Sporn, M. B. Chemoprevention of cancer. Lancet 342: 1211-1213; 1993.
13. Festing, F. W. M. Inbred strains in biochemical research. London: Macmillan Press; 1997.
14. Stravoravdi, P.; Toliou, Th.; Polyzonis, M. Protamine sulfate: A new chemopreventive role for an anti-angiogenic substance. Cancer J. 7(2):81-84; 1994.
15. James, S. Y.; Mercer, E.; Brady, M.; Binderup, L.; Colston, K. W. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol. 125(5):953-962; 1998.
16. 3 analog EB1089. Endocrinology 139(4):2102-2110; 1998.
17. Blutt, S. E.; Polek, T. C.; Stewart, L. V.; Kattan, M. W.; Weigel, N. L. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 60(4):779-782; 2000.
18. Lokeshwar, B. L.; Schwartz, G. G.; Selzer, M. G.; Burnstein, K. L.; Zhuang, S. H.; Block, N. L.; Binderup, L. Inhibition of prostate cancer metastasis in vivo: A comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol. Biomarkers Prev. 8(3):241-248; 1999.
19. 3 analog EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis. Colon Rectum 40(3): 317-321; 1997.
20. Colston, K. W.; James, S. Y.; Ofori-Kuragu, E. A.; Binderup, L.; Grant, A. G. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br. J. Cancer 76(8):1017-1020; 1997.
21. Hag, M.; Kremer, R.; Goltzman, D.; Rabbani, S. A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcaemia in vivo. J. Clin. Invest. 91(6):2416-2422; 1993.
22. Colston, K. W.; Mackay, A. G.; James, S. Y.; Binderup, L.; Chander, S.; Coombes, R. C. EB 1089: A new vitamin D analogue that inhibits growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 44(12):2273-2280; 1992.
23. Nickerson, T.; Huynh, H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth binding proteins. J. Endocrinol. 160(2):223-229; 1999.
24. Lippman, S. C.; Hong, K. W. 13-cis-retinoic acid and cancer chemoprevention. J. Natl. Cancer Inst. 13:111-115; 1992.
25. Reuber, M. D. Morphologic and biologic correlation of hyperplastic and neoplastic hepatic lesions occurring "spontaneously" in C3H XY hybrid mice. Br. J. Cancer 25:538-543; 1971.
26. Ward, J. M.; Vlahakis, G. Evaluation of hepatocellular neoplasms in mice. J. Natl. Cancer Inst. 61:807-811; 1978.
27. Dalhoff, K.; Astrup, L.; Bach-Hansrn, J.; Burcharth, F.; Haahr, H.; Hamberg, K.; Evans, R. J.; et al. Seocalcitol (EB1089), a vitamin D analogue, in hepatocellular carcinoma. Hepatology 28(4, Pt. 2):227A; 1998.
28. Kaczynski, J.; Hansson, G.; Remotti, H.; Wallerstedt, S. Spontaneous regression of hepatocellular carcinoma. Histopathology 32:147-150; 1998.